Pfizer Signs Vaccine Agreement with Cytos

September 9, 2008

Cytos Biotechnology AG (Schlieren, Switzerland) has entered into an exclusive global research, option, and license agreement with Pfizer Vaccines LLC (Pfizer, New York, NY) to research, develop, manufacture, and commercialize novel vaccines for a defined number of human diseases.

Cytos Biotechnology AG (Schlieren, Switzerland) has entered into an exclusive global research, option, and license agreement with Pfizer Vaccines LLC (Pfizer, New York, NY) to research, develop, manufacture, and commercialize novel vaccines for a defined number of human diseases.

After completing the research programs and exercising its options, Pfizer will acquire worldwide exclusive rights to commercialize certain vaccines, which are based on Cytos Biotechnology’s Immunodrug technology and that will incorporate specific disease targets, which are outside the scope of Cytos Biotechnology’s own programs. Cytos Biotechnology retains its rights to develop, manufacture, and commercialize vaccines against different disease targets in the same human diseases. Preclinical and clinical development, manufacturing, and commercialization of the vaccines will be Pfizer’s responsibility.

Cytos Biotechnology’s Immunodrug technology represents a versatile means to induce specific immune responses against disease-associated target molecules from a wide variety of sources, including the body’s own and foreign molecules. The Immunodrug technology brings the targets of choice into a highly repetitive format by chemically attaching them onto the surface of virus-like particles. The resulting Immunodrugs mimic a virus through this repetitive and particulate structure and are able to induce potent antibody responses against the selected targets with the goal of modulating or interfering with an ongoing disease process.

Cytos release (PDF)